Another Novo Nordisk class action alleges Ozempic caused vision loss

Ozempic lawsuit overview:

• Who: Plaintiff Robert J. Stottlemire is suing Novo Nordisk Inc.
• Why: Stottlemire claims Novo Nordisk’s drug Ozempic caused him to suffer NAION resulting in severe vision loss.
• Where: The Ozempic lawsuit was filed in Pennsylvania federal court.
• How to get help: If you experienced vision loss while taking Ozempic, Wegovy or Rybelsus and later diagnosed with NAION, you may be eligible to file a lawsuit.

A new class action lawsuit claims that Novo Nordisk’s drug Ozempic caused a patient to suffer severe vision loss, alleging that the pharmaceutical company failed to warn of the risks associated with its medication.

Plaintiff Robert J. Stottlemire filed the Ozempic vision loss class action lawsuit against Novo Nordisk Inc. on Feb. 3 in Pennsylvania federal court, alleging violations of state and federal consumer laws.

According to the Ozempic class action lawsuit, Stottlemire was prescribed Ozempic to treat his Type 2 diabetes. However, after using the medication, he said he developed non-arteritic anterior ischemic optic neuropathy (NAION), a condition that led to significant vision loss.

Stottlemire claims that Novo Nordisk failed to adequately warn consumers and healthcare providers about the potential risk of NAION associated with Ozempic.

He alleges that the company knew or should have known about the risk but failed to update the drug’s labeling to reflect this information.

Ozempic lawsuit: Novo Nordisk failed to update drug’s labeling about risk of NAION

Stottlemire’s Ozempic class action lawsuit argues that the labeling for Ozempic has been updated multiple times since its approval in 2017, but none of these updates included warnings about the risk of NAION.

The complaint also cites a study published in the Journal of the American Medical Association Ophthalmology, which found that patients taking Ozempic had a significantly higher risk of developing NAION compared to those not using the drug.

Stottlemire claims that Novo Nordisk’s failure to warn about the risk of NAION was a direct cause of his severe vision loss.

He alleges that if he and his healthcare providers had been aware of the risk, he would have chosen a different treatment option.

The Ozempic lawsuit brings claims for strict liability, negligence, breach of warranty, and violations of consumer protection laws. Stottlemire is seeking compensatory and punitive damages, as well as a trial by jury.

In September, a federal judge largely denied a motion by Eli Lilly and Novo Nordisk to dismiss a multidistrict litigation involving more than 2,600 lawsuits regarding GLP-1 weight-loss drugs like Ozempic and Wegovy.

What do you think of the claims made in this Ozempic class action lawsuit? Let us know in the comments.

The plaintiff is represented by Jonathan Orent, Ashley Hornstein, Grace Chandler, Michael G. Daly and Joshua M. Neuman of Motley Rice LLC.

The Ozempic lawsuit is Stottlemire v. Novo Nordisk Inc., Case No. 2:26-cv-00671, in the U.S. District Court for the Eastern District of Pennsylvania.

Read About More Class Action Lawsuits & Class Action Settlements:

• Lyft ordered to produce driver records in Uber sexual assault MDL
• Trader Joe’s and Ajinomoto Foods recall frozen chicken fried rice due to glass contamination
• Meta class action alleges $500M stock pump-and-dump scheme using scam ads
• ThredUp faces class action over mandatory handling fees not shown in item prices